Could a common gout drug protect hearts when statins fail?
NCT ID NCT06874192
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This pilot study tests whether low-dose colchicine, an anti-inflammatory drug already approved for heart disease, is safe and can reduce inflammation in 30 adults who cannot take statins due to side effects. Participants will take either colchicine or a placebo daily for four weeks. The goal is to see if colchicine can lower inflammatory markers like hs-CRP, potentially offering a new way to reduce heart risk in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-dose colchicine (0.5 mg daily)
What this could lead to
If it works, this could offer a way to lower heart disease risk in people who can't take statins.
What could go wrong
This is a very early, small pilot study with only 30 people over 4 weeks. It may not show clear benefits or safety issues may arise.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STATIN ADVERSE REACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••